Tillman Hartley LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Tillman Hartley LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Hold	508	–	–	0.06%	82
2026 Q1	$227K	Sell	508 -32	-6%	-$14.9K	0.06%	81
2025 Q4	$245K	Buy	540 +4	+0.7%	+$1.72K	0.06%	84
2025 Q3	$210K	Hold	536	–	–	0.05%	86
2025 Q2	$239K	Hold	536	–	–	0.07%	85
2025 Q1	$260K	Hold	536	–	–	0.08%	71
2024 Q4	$216K	Hold	536	–	–	0.06%	80
2024 Q3	$249K	Hold	536	–	–	0.07%	71
2024 Q2	$251K	Hold	536	–	–	0.09%	70
2024 Q1	$224K	Hold	536	–	–	0.08%	76
2023 Q4	$218K	Buy	+536	New	+$198K	0.08%	73

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tillman Hartley LLC's VRTX Position: Q2 2026 in Review

Tillman Hartley LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 508 shares worth $252K. The position accounts for 0.06% of the portfolio, ranked #82.

Tillman Hartley LLC first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $260K in Q1 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Tillman Hartley LLC held 508 shares of Vertex Pharmaceuticals worth $252K as of Q2 2026.
Tillman Hartley LLC left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.06% of Tillman Hartley LLC's portfolio in Q2 2026, its #82 holding.
Tillman Hartley LLC first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Tillman Hartley LLC's Vertex Pharmaceuticals position peaked at $260K in Q1 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Tillman Hartley LLC's 13F filing for Q2 2026, filed 6 Aug 2026.